01 Key Investment and Funding Activities in DNA Synthesis Market, 2026–2026 Company Funding/Investment (USD) Details Element Biosciences USD 175 Million In June 2026, Samsung Electronics invested USD 175 million through the company's Series E financing round to support commercialization of genomics and sequencing technologies. Ansa Biotechnologies USD 54.4 Million (Series B) In October 2025, the company raised funding to advance enzymatic DNA synthesis technology and expand commercial operations. Daisy Genomics USD 2.5 Million In January 2025, the company raised seed funding to expand genomics platform development and laboratory capabilities.
01 Rising Demand for High Complexity Synthetic Genes and Expanding Use of Synthetic DNA in AI-enabled Drug Discovery Drives Market The growing need for long, high complexity synthetic genes is driving DNA synthesis demand across synthetic biology, cell and gene therapy, and protein engineering workflows. Twist Bioscience reported 3QFY25 SynBio revenue of USD 35.2 million, up 7% YoY, while its NGS revenue rose 27 percent to USD 55.3 million, showing active uptake of DNA-based tools across research and translational applications. This is driving the market growth of the DNA synthesis industry.Increasing use of synthetic DNA in AI-enabled drug discovery, antibody engineering, CRISPR workflows, and nucleic acid therapeutic development is supporting market growth. Synthetic DNA serves as a critical input for designing, testing, and optimizing genetic sequences used in advanced biomedical applications. The growing need for high-throughput screening, precise gene editing, and rapid therapeutic candidate development is driving demand for accurate, scalable, and complex DNA synthesis solutions across pharmaceutical, biotechnology, and research organizations globally.
01 Biosecurity Screening Requirements and Complex Sequence Errors Restrain Market Increasing regulatory oversight surrounding synthetic nucleic acid procurement is creating additional compliance obligations for DNA synthesis providers and end users. Organizations must implement enhanced customer verification, sequence screening, supplier qualification, and procurement documentation processes to meet evolving biosecurity standards. These requirements can extend purchasing timelines, increase administrative costs, and complicate procurement workflows, particularly for academic institutions, biotechnology companies, and research organizations requiring rapid access to synthetic DNA products.Manufacturing highly complex and long DNA constructs remains a significant technical challenge for the industry. Sequences containing repetitive elements, extreme GC content, secondary structures, toxic genetic components, or large genomic regions often experience lower synthesis efficiency and higher error rates. Additional challenges associated with sequence assembly, verification, and quality control can increase production timelines and costs, limit scalability, and affect the reliable delivery of increasingly sophisticated synthetic DNA constructs.
01 Use of Enzymatic DNA Synthesis Platforms and 50 kb Sequence Synthesis Opens Opportunities for Market Players The ability to synthesize extremely long DNA sequences enables development of complex genetic constructs, engineered biological pathways, and advanced therapeutic designs that were previously difficult to create. This supports innovation in synthetic genomics, agricultural biotechnology, and cell and gene therapies while reducing development timelines. For example, researchers can design large multi-gene pathways for engineered cell-based treatments using a single synthesized construct.Biotech-driven anti-aging and regenerative DNA synthesis solutions are gaining momentum due to advances in cellular science and bioactive ingredient development. Research is focusing on improving skin renewal processes and reducing visible aging effects at a deeper biological level. These solutions target collagen regeneration and improved skin barrier function for long-term results. Companies are introducing lab-developed actives that work at a molecular level to improve skin quality. Consumer interest is rising in science-backed formulations that provide measurable improvements over time.
01 Policy Changes around Nucleic Acid Screening and Uneven Screening Adoption Challenges Market Growth Regulatory uncertainty challenges DNA synthesis providers as evolving government screening requirements may alter compliance obligations, supplier eligibility, and procurement processes. Frequent policy revisions can increase operational costs by requiring continuous updates to screening protocols and documentation systems. Differences in regulations across countries may also complicate cross-border transactions and limit market expansion opportunities.Expanding DNA synthesis access increases the need for robust customer and sequence screening, adding operational burdens for providers. For example, a university researcher ordering synthetic DNA may face additional identity verification, institutional approval checks, and documentation requirements, delaying procurement while suppliers maintain records and ensure compliance with biosecurity regulations.
May 2026 Twist Bioscience expanded its clonal genes portfolio with the early access launch of Complex Genes for long and complex sequence synthesis.
March 2026 Artis BioSolutions established a US-based synthetic DNA manufacturing hub in Boston using Syngoi Technologies’ enzymatic DNA platform.
January 2026 Artis BioSolutions announced the acquisition of Syngoi Technologies to expand synthetic DNA manufacturing capabilities for advanced therapy development.
January 2026 Integrated DNA Technologies partnered with Ansa Biotechnologies to add Clonal DNA and XL Clonal DNA products for longer, complex DNA constructs up to 50 kb
October 2025 Twist Bioscience and Element Biosciences launched the co-developed Trinity Freestyle Sequencing Workflow for AVITI systems, advancing sample-to-sequencer workflows.
September 2025 Twist Bioscience collaborated with Synthetic Design Lab to support next-generation therapeutics development using Twist’s DNA synthesis and biopharma capabilities.